Five Prime Therapeutics (NASDAQ:FPRX) Shareholders Are Liking The News That Wells Fargo Has Reiterated Their Outperform Rating on the Stock


Five Prime Therapeutics (NASDAQ:FPRX) Rating Reaffirmed

Wells Fargo has restated their Outperform rating on Five Prime Therapeutics (NASDAQ:FPRX) in analysts report issued to clients on Friday, 4 December.

From a total of 4 analysts covering Five Prime Therapeutics (NASDAQ:FPRX) stock, 4 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $48 while the lowest target price is $39. The mean of all analyst targets is $43.25 with a 6.80% above today’s ($37.92) stock price. Five Prime Therapeutics was the topic of 4 analyst reports since July 31, 2015 according to the firm StockzIntelligence Inc. Oppenheimer maintained shares on October 19 with “Outperform” rating. Citigroup initiated FPRX stock in a recent report from July 31 with “Buy” rating.

The stock closed the day at $37.92 during the previous session. It is down 82.84% since May 1, 2015 and is uptrending. It has outperformed by 85.62% the S&P500.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The company has a market cap of $1.04 billion. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230. It currently has negative earnings. FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R), that the Company is developing in rheumatoid arthritis.

According to Zacks Investment Research, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California.” Get a free copy of the Zacks research report on Five Prime Therapeutics Inc (FPRX).